Browse LAMTOR5

Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Lysosome.
Domain PF16672 Ragulator complex protein LAMTOR5
Function

As part of the Ragulator complex it is involved in amino acid sensing and activation of mTORC1, a signaling complex promoting cell growth in response to growth factors, energy levels, and amino acids. Activated by amino acids through a mechanism involving the lysosomal V-ATPase, the Ragulator functions as a guanine nucleotide exchange factor activating the small GTPases Rag. Activated Ragulator and Rag GTPases function as a scaffold recruiting mTORC1 to lysosomes where it is in turn activated. When complexed to BIRC5, interferes with apoptosome assembly, preventing recruitment of pro-caspase-9 to oligomerized APAF1, thereby selectively suppressing apoptosis initiated via the mitochondrial/cytochrome c pathway. Down-regulates hepatitis B virus (HBV) replication.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0006914 autophagy
GO:0007050 cell cycle arrest
GO:0008361 regulation of cell size
GO:0009615 response to virus
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0016236 macroautophagy
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0031929 TOR signaling
GO:0032006 regulation of TOR signaling
GO:0032008 positive regulation of TOR signaling
GO:0032535 regulation of cellular component size
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043200 response to amino acid
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0045786 negative regulation of cell cycle
GO:0045861 negative regulation of proteolysis
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0061462 protein localization to lysosome
GO:0071229 cellular response to acid chemical
GO:0071230 cellular response to amino acid stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0072665 protein localization to vacuole
GO:0090066 regulation of anatomical structure size
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0032947 protein complex scaffold
Cellular Component GO:0005765 lysosomal membrane
GO:0005770 late endosome
GO:0010008 endosome membrane
GO:0031902 late endosome membrane
GO:0044440 endosomal part
GO:0045121 membrane raft
GO:0071986 Ragulator complex
GO:0098589 membrane region
GO:0098852 lytic vacuole membrane
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04150 mTOR signaling pathway
Reactome R-HSA-2262752: Cellular responses to stress
R-HSA-380972: Energy dependent regulation of mTOR by LKB1-AMPK
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-1632852: Macroautophagy
R-HSA-109704: PI3K Cascade
R-HSA-109703: PKB-mediated events
R-HSA-162582: Signal Transduction
R-HSA-74752: Signaling by Insulin receptor
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-5628897: TP53 Regulates Metabolic Genes
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-165159: mTOR signalling
R-HSA-166208: mTORC1-mediated signalling
Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LAMTOR5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LAMTOR5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LAMTOR5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1970.419
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2570.939
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1550.949
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0710.838
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1270.916
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3270.84
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4320.297
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5440.757
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3390.864
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0980.969
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4070.919
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0430.528
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LAMTOR5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LAMTOR5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LAMTOR5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LAMTOR5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LAMTOR5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LAMTOR5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LAMTOR5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLAMTOR5
Namelate endosomal/lysosomal adaptor, MAPK and MTOR activator 5
Aliases XIP; MGC71071; HBx-interacting protein; hepatitis B virus x-interacting protein (9.6kD); HBXIP; hepatitis B ......
Chromosomal Location1p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LAMTOR5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.